Barcelona, May 4, 2023.
Pharmamel, the biotechnological Spin-Off of the University of Granada, announces the incorporation of Dr. Jordi Roma as the new "director of operations and clinical management" as well as a capital increase on the Capital Cell platform
Pharmamel, the biotechnological Spin-Off of the University of Granada, announces the incorporation of Dr. Jordi Roma as the new "director of operations and clinical management". Rome, with extensive experience in the development and approval of drugs, among others, faced the development of Aceclofenac, being the first Spanish active ingredient to obtain approval from the European Medicines Agency. He joins the Pharmamel team, for the management of the last clinical and regulatory phases of the intravenous melatonin drug for the treatment of Sepsis. To face this last challenge, the biotechnological company from Granada has announced that in the coming weeks it will launch a capital increase campaign in Capital Cell, a platform regulated by the CMNV, a leader in investment specialized in companies in the health and biotechnology sector. The round, already active at a private level, will be launched to the public in the coming weeks, with a minimum fundraising target of €800,000 and a maximum of €3,000,000, of which the company has already committed 35%. With the incorporation of Rome and this new capital increase campaign, the company intends to address the last phases of the intravenous melatonin drug for sepsis, concluding the clinical and regulatory process for its subsequent license.
Consulted sources affirm that in the company, the current executives as well as the Pharmamel investors are optimistic and convinced of being able to close the round at €3,000,000. For the first time, the company will be able to attract European investment, since Capital Cell has received authorization from the CNMV to operate under European law ECSP 2020/1503, which will allow it to start operating immediately in France, Germany , Italy, Portugal, Holland, Belgium and Denmark.
Contact Contact name: Pharmamel Communication Dept. Contact description: Pharmamel Communication Dept. Contact telephone number: 958 41 91 43